Cargando…

Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases

BACKGROUND: In patients with non-small cell lung cancer (NSCLC), 10%-40% will eventually develop brain metastases. We present the clinicopathologic, genomic, and biomarker landscape of a large cohort of NSCLC brain metastases (NSCLC-BM) samples. MATERIALS AND METHODS: We retrospectively analyzed 303...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Richard S P, Harries, Lukas, Decker, Brennan, Hiemenz, Matthew C, Murugesan, Karthikeyan, Creeden, James, Tolba, Khaled, Stabile, Laura P, Ramkissoon, Shakti H, Burns, Timothy F, Ross, Jeffrey S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Cancer Diagnostics and Molecular Pathology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526503/ https://www.ncbi.nlm.nih.gov/pubmed/35598205 http://dx.doi.org/10.1093/oncolo/oyac094

Ejemplares similares

Variable Genomic Landscapes of Advanced Melanomas with Heavy Pigmentation
por: Huang, Richard S P, et al.
Publicado: (2022)

Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay
por: Danziger, Natalie, et al.
Publicado: (2023)

Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers
por: Girard, Nicolas, et al.
Publicado: (2022)

Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression
por: Huang, Richard S.P., et al.
Publicado: (2021)

The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms
por: Liu, Man, et al.
Publicado: (2023)

Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer
por: Murugesan, Karthikeyan, et al.
Publicado: (2022)

Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study
por: Necchi, Andrea, et al.
Publicado: (2022)

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
por: Disel, Umut, et al.
Publicado: (2019)

Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901)
por: Peng, Wenying, et al.
Publicado: (2022)

Assessment of Oral Lesions With Tobacco Usage: A Cross-Sectional Clinicopathological Study in Sri Ganganagar, Rajasthan, India
por: Ramalingam, Karthikeyan, et al.
Publicado: (2023)

The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs
por: Mohamed, Luqmaan, et al.
Publicado: (2022)

Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network
por: Dias-Santagata, Dora, et al.
Publicado: (2022)

Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms
por: Franses, Joseph W., et al.
Publicado: (2017)

Evaluation of Serum Levels of Matrix MetalloProteinase-9 (MMP-9) in Oral Squamous Cell Carcinoma and Its Clinicopathological Correlation
por: Benitha, Georgia, et al.
Publicado: (2023)

Enhancing Next‐Generation Sequencing‐Guided Cancer Care Through Cognitive Computing
por: Patel, Nirali M., et al.
Publicado: (2017)

Quality of Life Assessment With European Organisation for Research and Treatment of Cancer Questionnaire (Head and Neck Module 43) and Its Clinicopathological Correlation Among Patients Treated for Oral Squamous Cell Carcinoma: An Exploratory Study
por: Ramalingam, Karthikeyan, et al.
Publicado: (2023)

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers
por: Hirshfield, Kim M., et al.
Publicado: (2016)

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
por: Kato, Shumei, et al.
Publicado: (2017)

Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer
por: Guo, Yun, et al.
Publicado: (2020)

Combined Expression of Plasma Thrombospondin‐2 and CA19‐9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach
por: Le Large, Tessa Y.S., et al.
Publicado: (2020)

Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large‐Scale Data to Inform Therapeutic Directions
por: Jardim, Denis L., et al.
Publicado: (2020)

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors
por: Takeda, Masayuki, et al.
Publicado: (2021)

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design
por: Ross, Jeffrey S., et al.
Publicado: (2020)

One‐Step Polymerase Chain Reaction‐Free Nanowire‐Based Plasma Cell‐Free DNA Assay to Detect EML4‐ALK Fusion and to Monitor Resistance in Lung Cancer
por: Lee, Youngjoo, et al.
Publicado: (2021)

Validation of a Circulating Tumor DNA‐Based Next‐Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing
por: Al Zoughbi, Wael, et al.
Publicado: (2021)

Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations
por: Koopman, Bart, et al.
Publicado: (2020)

Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary
por: Fusco, Michael J, et al.
Publicado: (2022)

Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents
por: Janse van Rensburg, Helena J, et al.
Publicado: (2022)

The Essentials of Multiomics
por: Marshall, John L, et al.
Publicado: (2022)

A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience
por: Pauli, Chantal, et al.
Publicado: (2021)

Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma
por: Yu, Pengfei, et al.
Publicado: (2021)

Liquid Biopsy-based Precision Therapy in Patients with Advanced Solid Tumors: A Real-world Experience from a Community-based Oncology Practice
por: Choucair, Khalil, et al.
Publicado: (2022)

Homologous Recombination Deficiency: Concepts, Definitions, and Assays
por: Stewart, Mark D, et al.
Publicado: (2022)

Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings
por: Sturgill, Emma G, et al.
Publicado: (2022)

Artificial Intelligence-based Radiomics in the Era of Immuno-oncology
por: Kang, Cyra Y, et al.
Publicado: (2022)

Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the COVID-19 Pandemic
por: Napolitano, Stefania, et al.
Publicado: (2022)

Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board
por: Green, Michelle F, et al.
Publicado: (2023)

Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers
por: Liu, Fangcen, et al.
Publicado: (2023)

Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator
por: Stenzinger, Albrecht, et al.
Publicado: (2023)

Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary
por: Wang, Xin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6lmssqqj9q7ck63skvgdj5p2kv